NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $38.25.

A number of analysts recently weighed in on NRXP shares. BTIG Research reaffirmed a “buy” rating and set a $25.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, March 24th. Ascendiant Capital Markets boosted their price target on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, April 27th.

NRx Pharmaceuticals Stock Down 8.4%

NRXP stock opened at $2.82 on Thursday. The firm has a market capitalization of $93.25 million, a PE ratio of -2.03 and a beta of 2.02. NRx Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $3.84. The stock has a 50-day simple moving average of $2.33 and a two-hundred day simple moving average of $2.32.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings results on Monday, March 23rd. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.28. The firm had revenue of $0.98 million during the quarter, compared to analysts’ expectations of $7.53 million. On average, equities research analysts anticipate that NRx Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Ethos Financial Group LLC grew its stake in NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after buying an additional 4,000 shares in the last quarter. Sjbenen Advisory LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at $41,000. One Wealth Management Investment & Advisory Services LLC lifted its holdings in shares of NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth $107,000. Finally, Two Sigma Investments LP grew its position in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.